Compare Figma Inc. Class A Common Stock (FIG) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figma Inc. Class A Common Stock vs Immunovant Inc. Common Stock — how do they compare? Figma Inc. Class A Common Stock trades at $21.24 (market cap $11.60B), while Immunovant Inc. Common Stock trades at $27.95 (market cap $5.93B). The key difference: Figma Inc. Class A Common Stock is the larger of the two by market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Figma Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and Immunovant Inc. Common Stock for 6 Days on average.
| FIG | IMVT | |
|---|---|---|
Market Cap | $11.60B | $5.93B |
Volume | 12,281,013 | 1,242,632 |
Sector | Technology | Health |
52-Week High | $63.82 | $44.96 |
52-Week Low | $16.84 | $17.41 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $10.00B | $5.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Immunovant (IMVT) trades at $28.71, down 2.61% with bearish technical signals despite strong analyst support. The company shows no revenue with substantial losses (-$413.84M net income) and negative margins, though it maintains a robust cash position from recent financing. Recent clinical setbacks, including the discontinuation of IMVT-1402 for cutaneous lupus, have pressured the stock, while multiple law firm investigations into potential fiduciary breaches add uncertainty.
The investment case hinges on IMVT-1402's success in other indications like Graves' disease, with a bullish analyst consensus (78% buy ratings) contrasting high execution risks. Key risks include clinical trial outcomes, cash burn, and legal overhangs. The stock's viability depends heavily on pipeline progress against a backdrop of persistent losses and volatile sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figma Inc. Class A Common Stock
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
